Barclays set a €85.00 ($98.84) price target on Merck KGaA (FRA:MRK) in a research note issued to investors on Monday morning, Borsen Zeitung reports. The brokerage currently has a sell rating on the healthcare company’s stock.
A number of other brokerages have also recently commented on MRK. Deutsche Bank set a €104.00 ($120.93) price objective on Merck KGaA and gave the stock a neutral rating in a research note on Monday. UBS Group set a €96.00 ($111.63) price objective on Merck KGaA and gave the stock a neutral rating in a research note on Thursday, November 14th. Credit Suisse Group set a €110.00 ($127.91) price objective on Merck KGaA and gave the stock a buy rating in a research note on Friday. Nord/LB set a €94.00 ($109.30) price objective on Merck KGaA and gave the stock a neutral rating in a research note on Friday, October 4th. Finally, Morgan Stanley set a €96.00 ($111.63) price objective on Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating to the company. Merck KGaA has a consensus rating of Hold and a consensus target price of €103.06 ($119.84).
Shares of FRA MRK traded up €0.05 ($0.06) during midday trading on Monday, hitting €108.20 ($125.81). The stock had a trading volume of 546,294 shares. The company’s 50-day simple moving average is €105.73 and its 200 day simple moving average is €97.11. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).
Merck KGaA Company Profile
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: Earnings Reports
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.